Hulin Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hulin Chang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Bing Wu
Department of Geriatrics, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China
2 shared publicationsHui Li
Department of Hepatobiliary Surgery, Shaanxi Provincial People’s Hospital, Xi’an, China
2 shared publicationsSinan Liu
Department of SICU, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 shared publicationsXilin Geng
Department of Hepatobiliary Surgery, Shaanxi Provincial People’s Hospital, Xi’an, China
2 shared publicationsZeyu Li
Department of General Surgery, Shaanxi Provincial People’s Hospital, Xi’an, China
2 shared publications- Bobo Zheng
Department of General Surgery, Shaanxi Provincial People’s Hospital, Xi’an, China
1 shared publication
Latest Publications
- 24 May 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 285, 156561
Upregulation of TWNK promotes proliferation and invasion of liver cancer by enhancing mitochondrial respiration
- 24 May 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 285, 156561
Upregulation of TWNK promotes proliferation and invasion of liver cancer by enhancing mitochondrial respiration
- Open Access
- 6 January 2026
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
SLC25A39 facilitates Sorafenib resistance in hepatocellular carcinoma by inhibiting mitochondrial oxidative stress-induced ferroptosis
Mitochondria are intracellular double-membrane-bound organelles that play a crucial role in maintaining redox homeostasis, disruptions of which are closely linked to oncogenesis. Recent investigations have identified SLC25A39 as a mitochondrial membrane transporter essential for the importation of glutathione (GSH) into mitochondria. However, the roles of SLC25A39 in human malignancies remain inadequately understood. Here, we observed a marked upregulation of SLC25A39, which correlates with poor prognostic outcomes in hepatocellular carcinoma (HCC). The silencing of SLC25A39 resulted in a reduction of HCC cell viability and proliferation through inducing ferroptosis via increasing mitochondrial ROS accumulation. In contrast, the overexpression of SLC25A39 enhanced survival and proliferation of HCC cells by promoting ferroptosis evasion through reducing mitochondrial ROS accumulation. Importantly, we discovered that the expression of SLC25A39 was notably increased in Sorafenib-resistant HCC cells, and silencing of SLC25A39 could sensitize HCC cells to ferroptotic cell death and augment the therapeutic efficacy of Sorafenib against HCC. Overall, our investigation provides comprehensive evidence that SLC25A39 is a critical regulator of ferroptosis evasion and proposes its potential as a therapeutic target to improve the effectiveness of Sorafenib in the treatment of HCC.
- 6 January 2026
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Open AccessSLC25A39 facilitates Sorafenib resistance in hepatocellular carcinoma by inhibiting mitochondrial oxidative stress-induced ferroptosis
Mitochondria are intracellular double-membrane-bound organelles that play a crucial role in maintaining redox homeostasis, disruptions of which are closely linked to oncogenesis. Recent investigations have identified SLC25A39 as a mitochondrial membrane transporter essential for the importation of glutathione (GSH) into mitochondria. However, the roles of SLC25A39 in human malignancies remain inadequately understood. Here, we observed a marked upregulation of SLC25A39, which correlates with poor prognostic outcomes in hepatocellular carcinoma (HCC). The silencing of SLC25A39 resulted in a reduction of HCC cell viability and proliferation through inducing ferroptosis via increasing mitochondrial ROS accumulation. In contrast, the overexpression of SLC25A39 enhanced survival and proliferation of HCC cells by promoting ferroptosis evasion through reducing mitochondrial ROS accumulation. Importantly, we discovered that the expression of SLC25A39 was notably increased in Sorafenib-resistant HCC cells, and silencing of SLC25A39 could sensitize HCC cells to ferroptotic cell death and augment the therapeutic efficacy of Sorafenib against HCC. Overall, our investigation provides comprehensive evidence that SLC25A39 is a critical regulator of ferroptosis evasion and proposes its potential as a therapeutic target to improve the effectiveness of Sorafenib in the treatment of HCC.
- Open Access
- 18 July 2024
- Published by Taylor & Francis in Redox Report
- Vol. 29 (1) , 2373657
Methane saline suppresses ferroptosis via the Nrf2/HO-1 signaling pathway to ameliorate intestinal ischemia–reperfusion injury
Intestinal ischemia-reperfusion (I/R) injury is a multifactorial and complex clinical pathophysiological process. Current research indicates that the pathogenesis of intestinal I/R injury involves various mechanisms, including ferroptosis. Methane saline (MS) has been demonstrated to primarily exert anti-inflammatory and antioxidant effects in I/R injury. In this study, we mainly investigated the effect of MS on ferroptosis in intestinal I/R injury and determined its potential mechanism. In vivo and in vitro intestinal I/R injury models were established to validate the relationship between ferroptosis and intestinal I/R injury. MS treatment was applied to assess its impact on intestinal epithelial cell damage, intestinal barrier disruption, and ferroptosis. MS treatment led to a reduction in I/R-induced intestinal epithelial cell damage and intestinal barrier disruption. Moreover, similar to treatment with ferroptosis inhibitors, MS treatment reduced ferroptosis in I/R, as indicated by a decrease in the levels of intracellular pro-ferroptosis factors, an increase in the levels of anti-ferroptosis factors, and alleviation of mitochondrial damage. Additionally, the expression of Nrf2/HO-1 was significantly increased after MS treatment. However, the intestinal protective and ferroptosis inhibitory effects of MS were diminished after the use of M385 to inhibit Nrf2 in mice or si-Nrf2 in Caco-2 cells. We proved that intestinal I/R injury was mitigated by MS and that the underlying mechanism involved modulating the Nrf2/HO-1 signaling pathway to decrease ferroptosis. MS could be a promising treatment for intestinal I/R injury.
- 18 July 2024
- Published by Taylor & Francis in Redox Report
- Vol. 29 (1) , 2373657
Open AccessMethane saline suppresses ferroptosis via the Nrf2/HO-1 signaling pathway to ameliorate intestinal ischemia–reperfusion injury
Intestinal ischemia-reperfusion (I/R) injury is a multifactorial and complex clinical pathophysiological process. Current research indicates that the pathogenesis of intestinal I/R injury involves various mechanisms, including ferroptosis. Methane saline (MS) has been demonstrated to primarily exert anti-inflammatory and antioxidant effects in I/R injury. In this study, we mainly investigated the effect of MS on ferroptosis in intestinal I/R injury and determined its potential mechanism. In vivo and in vitro intestinal I/R injury models were established to validate the relationship between ferroptosis and intestinal I/R injury. MS treatment was applied to assess its impact on intestinal epithelial cell damage, intestinal barrier disruption, and ferroptosis. MS treatment led to a reduction in I/R-induced intestinal epithelial cell damage and intestinal barrier disruption. Moreover, similar to treatment with ferroptosis inhibitors, MS treatment reduced ferroptosis in I/R, as indicated by a decrease in the levels of intracellular pro-ferroptosis factors, an increase in the levels of anti-ferroptosis factors, and alleviation of mitochondrial damage. Additionally, the expression of Nrf2/HO-1 was significantly increased after MS treatment. However, the intestinal protective and ferroptosis inhibitory effects of MS were diminished after the use of M385 to inhibit Nrf2 in mice or si-Nrf2 in Caco-2 cells. We proved that intestinal I/R injury was mitigated by MS and that the underlying mechanism involved modulating the Nrf2/HO-1 signaling pathway to decrease ferroptosis. MS could be a promising treatment for intestinal I/R injury.
- 16 March 2020
- Published by Wiley in Liver International
- Vol. 40 (7) , 1756-1769
Over‐expression of TFB2M facilitates cell growth and metastasis via activating ROS‐Akt‐NF‐κB signalling in hepatocellular carcinoma
Background & Aims Human TFB2M (mitochondrial transcription factor B2) is a key regulator of mitochondria transcription. Our bioinformatic analysis based on the cancer genome atlas (TCGA) data revealed an aberrant over‐expression of TFB2M in hepatocellular carcinoma (HCC). However, the functional roles of TFB2M in tumorigenesis remains unexplored, including HCC. Methods The expression and clinical significance of TFB2M were evaluated by qRT‐PCR and western blot analysis. The biological effects and underlying mechanisms of TFB2M in HCC were determined by cell proliferation, colony formation, cell cycle, apoptosis, migration, and invasion assays. Results TFB2M was commonly up‐regulated in HCC mainly due to the down‐regulation of miR101‐3p, which significantly correlated with poor survival of HCC patients. Functional experiments revealed that TFB2M significantly promoted HCC cell proliferation, migration, and invasion, while inhibited apoptosis in vitro and promoted xenograft tumorigenesis and lung metastasis in nude mice models in vivo. Mechanistically, increased production of reactive oxygen species (ROS) and subsequently activated Akt/NF‐κB signaling was found to be involved in the promotion of growth and metastasis by TFB2M in HCC cells. Conclusions these findings suggest that TFB2M plays a pivotal oncogenic role in HCC cells through activating ROS‐Akt‐NF‐κB signaling pathway.
- 16 March 2020
- Published by Wiley in Liver International
- Vol. 40 (7) , 1756-1769
Over‐expression of TFB2M facilitates cell growth and metastasis via activating ROS‐Akt‐NF‐κB signalling in hepatocellular carcinoma
Background & Aims Human TFB2M (mitochondrial transcription factor B2) is a key regulator of mitochondria transcription. Our bioinformatic analysis based on the cancer genome atlas (TCGA) data revealed an aberrant over‐expression of TFB2M in hepatocellular carcinoma (HCC). However, the functional roles of TFB2M in tumorigenesis remains unexplored, including HCC. Methods The expression and clinical significance of TFB2M were evaluated by qRT‐PCR and western blot analysis. The biological effects and underlying mechanisms of TFB2M in HCC were determined by cell proliferation, colony formation, cell cycle, apoptosis, migration, and invasion assays. Results TFB2M was commonly up‐regulated in HCC mainly due to the down‐regulation of miR101‐3p, which significantly correlated with poor survival of HCC patients. Functional experiments revealed that TFB2M significantly promoted HCC cell proliferation, migration, and invasion, while inhibited apoptosis in vitro and promoted xenograft tumorigenesis and lung metastasis in nude mice models in vivo. Mechanistically, increased production of reactive oxygen species (ROS) and subsequently activated Akt/NF‐κB signaling was found to be involved in the promotion of growth and metastasis by TFB2M in HCC cells. Conclusions these findings suggest that TFB2M plays a pivotal oncogenic role in HCC cells through activating ROS‐Akt‐NF‐κB signaling pathway.
- Open Access
- 1 December 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 18, 1009-1022
NPAS2 Contributes to Liver Fibrosis by Direct Transcriptional Activation of Hes1 in Hepatic Stellate Cells
- 1 December 2019
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 18, 1009-1022
Open AccessNPAS2 Contributes to Liver Fibrosis by Direct Transcriptional Activation of Hes1 in Hepatic Stellate Cells